retatrutide drug trial VisualAbstract: reduces body weight by 17.5% in patients with obesity ESC 2024: Retatrutide improves lipid

Sermorelin is a compounded prescription medication that requires evaluation by a licensed clinician

Effect of subcutaneous semaglutide vs placebo as an adjunct to intensive behavioral therapy on body weight (STEP 3)

The content presented here does not constitute medical or veterinary advice, and should not be used to guide clinical decisions for animals or humans

At 80 weeks, all doses of retatrutide (4 mg, 9 mg, and 12 mg) met the primary and key secondary endpoints for obesity, delivering clinically meaningful weight loss

This distinguishes these agents from sodium-glucose cotransporter-2 (SGLT2) inhibitors, another diabetes medication class that does carry a well-documented increased risk of genital mycotic infections due to their mechanism of causing glucosuria

Originally developed to treat diabetes, GLP-1 receptor agonists (commonly known as GLP-1s) have re-shaped the weight management market